ArticleScientific reports2025
Antioxidant activity, molecular docking, and modeling pharmacokinetics study of some benzo[f]quinoline candidates.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Quinazoline-tethered thiazolo[3,2-RSC advances · 2026Article
- Synthesis of Quinazoline Derivatives and Mechanistic Approaches in Lung and Breast Cancers.Molecules (Basel, Switzerland) · 2026Article
- Exploring the mechanism of Shengmai San in treating lung adenocarcinoma based on bioinformatics and molecular dynamics simulation.Medicine · 2026Article
- Synthesis, computational studies, and biological evaluation of novel cyanoacrylamides as potential anticancer agents.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploring insecticidal activity and SAR study of newly synthesized Benzo[h]quinoline-based heterocycles against Aphis craccivora Koch. and Culex pipiens L. Larvae.Scientific reports · 2026Article
- Synthesis and insecticidal activity of some pyrazole, pyridine, and pyrimidine candidates against Culex pipiens L. larvae.Scientific reports · 2025Article
- Synthesis, antiproliferative screening, and molecular docking of some heterocycles derived from N-(1-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-3-hydrazineyl-3-oxoprop-1-en-2-yl)benzamide.Scientific reports · 2025Article
- Emerging and Versatile Non-Mammalian Model Organisms for Studying the In Vivo Antioxidant Properties of Food-Derived Bioactive Compounds.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzoquinolines were found in many pharmaceuticals and natural products and were utilized as templates for the synthesis of many drugs. Thus, 3-(3-chlorobenzo[f]quinolin-2-yl)-2-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)acrylonitrile was prepared as a key building substrate, using arylidene ethyl cyanoacetate derivative 3, and reacted with diverse mono- and bi-dentate nitrogen nucleophiles aiming to construct new heterocycles based on a benzo[f]quinoline core, for example quinazolinone, imidazoline, oxadiazolinone, and benzimidazole derivatives. The antioxidant activity of the synthesized compounds was evaluated, using ascorbic acid as a reference, and revealed the highest potency of benzimidazole derivative 19, which may be attributed to the aromaticity and extended conjugation. These findings were supported by in silico studies. A molecular docking simulation was performed to disclose the modes of interactions of benzimidazole 19 toward HCV NS5B polymerase. It exhibited a binding energy greater than that of co-crystallized ligand, referring to strong binding to certain key nucleobases and amino acids (CYS 366 and ASN 411) of HCV NS5B polymerase through hydrogen bonding and pi-hydrogen interactions, revealing its potential usage as an antioxidant agent. DFT simulation for the active compounds were studied to determine the molecular geometry and frontier orbitals of the potent compounds. Regarding ADME simulation, compounds 3, 9, and 17 exhibited a high GI absorption and good bioavailability score of 0.85, 0.55, and 0.55, respectively. The variance in GI absorption might depict the differences in observed antioxidant efficacy of compounds. Also, they showed gastrointestinal tract (GIT) absorption due to their being in the BOILED-EGG chart white area. The potent compounds 3, 9, 13, 17, and 19 exhibited fair TPSA and predicted to exhibit good passive oral absorption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.